Racivir
From Wikipedia, the free encyclopedia
|
Racivir
|
|
| Systematic (IUPAC) name | |
| 4-Amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C8H10FN3O3S |
| Mol. mass | 247.25 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1]
[edit] References
- ^ AIDSmeds.com - Racivir. Retrieved on 2008-03-21.
|
|||||||||||||||||||||||||||||

